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 Steroid-resistant nephrotic syndrome 
(SRNS), which typically manifests histo-
logically as focal segmental glomerulo-
sclerosis (FSGS), remains one of the most 
intractable kidney diseases. In children it 
carries a 30 % risk of recurrence in a kid-
ney transplant. 
 Following identi% cation of the  podocin 
gene ( NPHS2 ), 1 it came as somewhat of a 
surprise to the nephrology community 
that 10 – 28 % of all nonfamilial childhood 
cases of SRNS are caused by recessive 
 podocin mutations as the single su+  cient 
cause of the disease. 2 (, e term  ‘ recessive 
mutations ’ refers to the fact that mutations 
in both parental  podocin alleles have been 
detected in the patient and are necessary 
and su+  cient for disease manifestation.) 
Furthermore, an important correlation 
between genotype and treatment response 
was revealed in the % nding that patients 
with two recessive mutations of the 
 podocin gene do not respond to standard 
steroid treatment but on the other hand 
have a strongly reduced likelihood of 
FSGS recurrence in a renal transplant 
(35 % versus 8 % ). 3,4 These findings are 
clinically quite relevant. , ey allow for an 
etiology-based disease classi% cation of 
SRNS / FSGS, as the recessive mutations 
embody the primary cause of the disease. 
In other words, a mutation in a single gene 
alone is su+  cient to cause disease in a 
given patient, although di4 erent  ‘ single-
gene, ’ or  ‘ monogenic, ’ causes may be active 
in di4 erent patients. , us, recessive dis-
ease genes probably represent the most 
cogent basis for  ‘ genetic personalized 
medicine, ’ based on their full penetrance 
(that is, a patient who carries two  podocin 
mutations will develop FSGS with 
near certainty). In addition, with very 
few exceptions, 5 all monogenic forms of 
SRNS lead to end-stage kidney disease 
(ESKD). 
 From the emerging list of monogenic 
causes of SRNS, it soon became apparent 
that there is a strong correlation between 
the causative gene mutations and the age 
 1 Department of Pediatrics, University of Michigan , 
 Ann Arbor ,  Michigan ,  USA ;   2 Department of Human 
Genetics, University of Michigan ,  Ann Arbor , 
 Michigan ,  USA ;   3 Howard Hughes Medical Institute, 
University of Michigan ,  Ann Arbor ,  Michigan ,  
USA  
 Correspondence: Friedhelm Hildebrandt, 
8220C Medical Science Research Building III, 
Box 5646, 1150 W. Medical Center Drive, 
Ann Arbor, Michigan 48109, USA. 
E-mail:  fhilde@umich.edu 
 Specific  podocin mutations 
determine age of onset of 
nephrotic syndrome all the 
way into adult life 
 Friedhelm  Hildebrandt 1 , 2 , 3 and  Saskia F.  Heeringa 1 
 In steroid-resistant nephrotic syndrome (SRNS) Machuca  et al. report 
that mutations of the recessive  podocin gene cause adult-onset SRNS 
if the R229Q genetic variant occurs in a compound heterozygous state 
with another  podocin mutation. Learning to tell apart the specific allele 
combinations of  podocin mutations will be important for prognosis, 
genetic counseling in living related kidney donation, accurate etiologic 
classification within treatment studies, and the understanding of 
podocin function. 
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of onset of FSGS or ESKD, in at least two 
ways ( Figure 1 ): 
 First, mutations in di4 erent genes man-
ifest with SRNS at di4 erent ages. Speci% -
cally, recessive genes that cause SRNS, 
including  nephrin ( NPHS1 ),  podocin 
( NPHS2 ),  laminin-  2 ( LAMB2 ), and  phos-
pholipase C-  1 ( PLCE1 ), lead to child-
hood-onset SRNS, whereas the extremely 
rare mutations in dominant genes, includ-
ing  actinin-  4 ( ACTN4 ) and  TRPC6 , 
cause adult-onset disease ( Figure 1 ). 6,7 
(, e genes  CD2AP and  WT1 represent 
somewhat of an exception to the rule.) In 
addition, the earlier the onset of SRNS, the 
more likely that it is of monogenic 
origin, as 85 % of all SRNS manifesting in 
the % rst 3 months of life and 66 % of all 
SRNS manifesting in the % rst year of life 
are caused by mutations in one of only 
four genes,  nephrin ,  podocin ,  LAMB2 , 
or  WT1 . 8 
 Second, for recessive  podocin mutations, 
the combination of the two parental alleles 
(that is, the specific mutation in each 
parental copy of the  podocin gene) deter-
mines the age of onset of SRNS and 
ESKD. 9 Specifically, the presence of at 
least one mutation that truncates the pro-
tein (for example, a stop codon) together 
with one other mutation, or the presence 
of the mutation R138Q homozygously, 
leads to early onset of SRNS at a median 
age of 1.7 years. In contrast, the presence 
of two missense mutations causes later 
onset at a median of 4.7 years ( Figure 1a 
and b ). 9 , e R138Q mutation is derived 
from a genetic founder in Western Europe. 
These findings revealed that podocin 
mutations are subject to  ‘ multiple allelism, ’ 
in which the clinical severity or age of 
onset of disease varies by the specific 
nature and combination of the two muta-
tions (alleles) that a patient carries. , is is 
most clearly conveyed by the fact that 
speci% c alterations of the podocin protein 
result in different degrees of loss of 
function. 
 Interestingly, complete loss of function 
of podocin may lead to such early mani-
festation that it interferes with glomerular 
development, leading to the morphologic 
phenotype of congenital nephrotic syn-
drome of the Finnish type (CNS-FT) 
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of one and the same causative gene 
( Figure 1c ). 5  Within the spectrum of 
age-related onset determined by di4 erent 
podocin mutations, adult onset was rarely, 
if ever, seen (where adult onset is de% ned 
as onset of proteinuria after 18 years 
of life). 11 – 14 
 Machuca  et al . 15 (this issue) now dem-
onstrate that recessive  podocin mutations 
may also cause adult-onset SRNS if a cer-
tain kind of mutation is involved. , e spe-
cific mutation, known as R229Q, may 
have gone unrecognized for some time 
because of its  ‘ bland ’ nature. R229Q was 
previously considered by most to repre-
sent an  ‘ innocuous polymorphism ’ of 
 podocin because it occurs in 2 – 4 % of 
healthy individuals. , is assessment was 
based on a large meta-analysis 16 and on a 
lack of clear evidence of a functional 
defect resulting from R229Q, although, 
early on, a potential genetic interaction 
between the R229Q variant of  podocin and 
 nephrin was described, 17,18 as well as the 
presence of compound heterozygous 
podocin mutations that included R229Q. 19 
The distinction between a  ‘ bona fide ’ 
mutation and an innocuous polymor-
phism is usually based on the % ndings that 
the former is absent from 100 healthy 
control individuals, can be demonstrated 
to be deleterious in an  in vitro or  in vivo 
assay or animal model, or leads to concep-
tual loss of function of the protein (for 
example, by introducing a premature stop 
codon, or changing an amino acid residue 
of the encoded protein that is highly con-
served throughout evolution or changing 
it to a functionally very di4 erent residue). 
In the R229Q variant, none of these dis-
tinctions was conclusive. 
 Machuca  et al. 15 systematically followed 
up on the initial evidence that R229Q 
might in fact not represent an innocuous 
polymorphism but might, when com-
bined with a second bona % de podocin 
mutation, rather cause adult-onset SRNS 
as initially described by Tsukaguchi  et al. 19 
, e authors here provide evidence that 
recessive podocin mutations may not be 
as rare in adult-onset SRNS as previously 
thought, although some groups described 
them as virtually absent. 11 – 14,20 
 Machuca  et al. 15 sequenced the entire 
coding region of podocin in 455 patients 
from unrelated families with SRNS who 
rather than to FSGS ( Figure 1c and d ). 8 
, e severity of the R138Q allele was con-
firmed in a knock-in mouse model of 
nephrotic syndrome, in which diffuse 
mesangial sclerosis (DMS) resulted. 10 , is 
discovery demonstrated that the histo-
logic distinctions of DMS, CNS-FT, and 
FSGS represent only intermediate pheno-
types that may di4 er between patients on 
the basis of the speci% c allelic mutations 
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 Figure 1  |  Steroid-resistant nephrotic syndrome may be caused by single-gene mutations 
in up to 25 % of patients, depending on age group. ( a and  b ) The younger the patient, the 
more likely it is that steroid-resistant nephrotic syndrome (SRNS) is caused by a single-gene 
( ‘ monogenic ’ ) defect. The age of onset of SRNS and end-stage kidney disease depends on 
two parameters: (1) The causative gene itself determines onset. As a rule, recessive genes 
( LAMB2 ,  nephrin ,  PLCE1 , and  podocin ) cause early onset of nephrotic syndrome (NS) during fetal 
development, during the first 3 months of life, or during early childhood (see the red to yellow 
part of the spectrum). In contrast, dominant gene mutations ( ACTN4 ,  TRPC6 ,  CD2AP ) usually lead 
to adult-onset SRNS (see the purple part of the spectrum), with the exception of  WT1 mutations, 
which cover a broad age range. (2) The specific mutation of a gene ( ‘ allelic differences ’ ) determines 
onset. In  podocin ( NPHS2 ), a truncation mutation in a compound heterozygous state with any 
other podocin mutation, or the presence of two R138Q mutations, leads to early onset (mean 1.75 
years), whereas the presence of at least one missense mutation (other than R138Q) leads to onset 
in later childhood (mean 4.17 years). Machuca  et al. 15 now demonstrate that the variant R229Q 
together with another  podocin mutation may cause adult onset of SRNS (>18 years) ( a and  b ). Both 
parameters, the specific mutated gene and the specific mutation within that gene, determine 
the age of onset of SRNS. ( c and  d ) The specific phase of development at which a gene mutation 
becomes operative determines the resulting renal histology. Typically, early loss of gene function 
causes early, congenital onset (  <  3 months of life) with a developmental, morphogenic defect 
that interferes with glomerulogenesis and that will manifest histologically as diffuse mesangial 
sclerosis (DMS) or congenital nephrotic syndrome of the Finnish type (CNS-FT). In contrast, later 
loss of gene function causes onset in childhood or adult life with a defect of tissue maintenance 
and repair that manifests histologically as focal segmental glomerulosclerosis (FSGS). For example, 
 LAMB2 mutations always cause severe DMS or congenital nephrotic syndrome (CNS) (a and b). 
Nephrin causes CNS-FT in most cases but occasionally may cause childhood-onset SRNS on the 
basis of   ‘ mild ’ mutations. 21  PLCE1 mutations represent the most frequent cause of DMS; however, 
a missense mutation can  ‘ rescue ’ toward an FSGS phenotype. 5  Podocin mutations typically cause 
childhood NS but can cause up to 50 % of CNS, if R138Q or two truncating mutations are present 8 
( a and  b ).  WT1 and  PLCE1 may cause both the developmental defect of DMS and the degenerative 
defect of FSGS. It seems that in FSGS the repair of glomerular tufts requires reinitiation of 
developmental programs involving  WT1 and  PLCE1 . If these mechanisms go awry, scarring or 
FSGS will result. 
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had not responded to immunosuppressive 
therapy and who did not have post-trans-
plantation recurrence. , ey found a sig-
ni% cantly higher prevalence of the R229Q 
variant of  podocin in European patients 
versus controls. , e total cohort repre-
sented patients from Europe (55.2 % ), the 
Middle East (11.9 % ), North Africa 
(14.7 % ), South America (10.3 % ), and 
other regions (7.9 % ). , e authors identi-
% ed homozygous or compound hetero-
zygous podocin mutations in 65 of 455 
di4 erent families (14.3 % ). In addition, 
they detected 27 compound heterozygous 
individuals from di4 erent families (5.9 % 
of all families examined) who carried a 
heterozygous R229Q variant with a bona 
fide  podocin mutation (most of these 
mutations were missense mutations). 
, irteen of these individuals were from 
Europe and 14 were from South America. 
, e authors detected the following novel 
correlation between genotype and age of 
onset of SRNS: the patients with com-
pound heterozygosity for the R229Q 
variant and a bona % de podocin mutation 
developed adult onset of SRNS at a median 
age of 19 years (and ESKD at 28 years), 
whereas the patients with two bona % de 
podocin mutations exhibited onset of 
SRNS in infancy or childhood with a 
median onset of SRNS at 1.1 years (and 
ESKD at 8 years) as described before for 
bona % de mutations. 
 , e notion that compound heterozy-
gosity for the R229Q variant and a bona 
fide podocin mutation represents a 
prevalent adult-onset constellation of 
podocin mutations was con% rmed by the 
authors ’ % nding that among 119 patients 
who presented with SRNS aD er 18 years 
of age, 18 (15 % ) presented with this con-
stellation, but none was found with two 
bona % de podocin mutations in this age 
group. Although these results would leave 
85 % of adult-onset cases unexplained by 
podocin mutations, the % ndings strongly 
suggest that the allelic constellation of 
compound heterozygosity for R229Q 
together with a bona fide podocin 
mutation represents a genetic finding 
characteristic of onset of SRNS in young 
adults. Mutations should consequently 
be investigated in these patients to 
better characterize this patient cohort 
in the future. 
 Interestingly, R229Q was found rela-
tively oD en in a compound heterozygous 
state with the A284  V mutation. Two of 
these patients were from Spain, and 13 
were of Hispanic descent living in South 
America. It will be interesting to see 
whether the A284  V mutation occurs on a 
conserved haplotype introduced by a 
Spanish founder. Seeking speci% c R229Q /
 A284  V compound heterozygosity in 
patients of Spanish descent might help to 
better define the natural history and 
potential treatment responses of their 
SRNS. In % ve families in whom R229Q 
occurred homozygously in some indi-
viduals, there was incomplete penetrance, 
indicating the weak action of R229Q. , is 
study also emphasizes that the functional 
signi% cance of certain mutations such as 
R229Q in recessive diseases may be evalu-
ated only in the context of the speci% c 
second mutation present in the compound 
heterozygous state. 
 Learning to tell apart the different 
 ‘ H avors ’ of speci% c allele combinations of 
 podocin mutations will be very important 
for making a prognosis, for adequate 
genetic counseling and counseling for liv-
ing related kidney donation, and for accu-
rate etiologic classification within 
treatment studies, as well as for the under-
standing of podocin function. 
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